Marco Gaviraghi

Dr. Marco Gaviraghi

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2015 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
BRBeatrice Rondinelli
Beatrice Rondinelli
HSHélène Schwerer
Hélène Schwerer
EAElena Antonini
Elena Antonini
MGMarco Gaviraghi
Marco Gaviraghi
ALAlessio Lupi
Alessio Lupi
GTGiovanni Tonon
Giovanni Tonon
DNA replication is a tightly regulated process that initiates from multiple replication origins and leads to the faithful transmission of the genetic material. For proper DNA replication, the chromatin surrounding origins needs to be remodeled. However, remarkably little is known on which epigenetic changes are required to allow the firing of replication origins. Here, we show that the histone demethylase KDM5C/JARID1C is required for proper DNA replication at early origins. JARID1C dictates the assembly of the pre-initiation complex, driving the binding to chromatin of the pre-initiation proteins CDC45 and PCNA, through the demethylation of the histone mark H3K4me3. Fork activation and histone H4 acetylation, additional early events involved in DNA replication, are not affected by JARID1C downregulation. All together, these data point to a prominent role for JARID1C in a specific phase of DNA replication in mammalian cells, through its demethylase activity on H3K4me3.

12 March 2012 in Oncogene
Verified
Journal Article
Open access
PDF file
RPR Palorini
R Palorini
DRDomenico De Rasmo
Domenico De Rasmo
MGMarco Gaviraghi
Marco Gaviraghi
LDL Sala Danna
L Sala Danna
ASAnna Signorile
Anna Signorile
SPSergio Papa
Sergio Papa
The Warburg effect in cancer cells has been proposed to involve several mechanisms, including adaptation to hypoxia, oncogenes activation or loss of oncosuppressors and impaired mitochondrial function. In previous papers, it has been shown that K-ras transformed mouse cells are much more sensitive as compared with normal cells to glucose withdrawal (undergoing apoptosis) and present a high glycolytic rate and a strong reduction of mitochondrial complex I. Recent observations suggest that transformed cells have a derangement in the cyclic adenosine monophosphate/cAMP-dependent protein kinase (cAMP/PKA) pathway, which is known to regulate several mitochondrial functions. Herein, the derangement of the cAMP/PKA pathway and its impact on transformation-linked changes of mitochondrial functions is investigated. Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels. Several of these effects were almost completely prevented by inhibiting the PKA activity. Short-time treatment with compounds favoring mitochondrial fusion strongly decreased the cellular ROS levels especially in transformed cells. These findings support the notion that glucose shortage-induced apoptosis, specific of K-ras-transformed cells, is associated to a derangement of PKA signaling that leads to mitochondrial complex I decrease, reduction of ATP formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs.

29 October 2018 in The EMBO Journal
Verified
Journal Article
Closed access
PDF file
MGMarco Gaviraghi
Marco Gaviraghi
CVClaudia Vivori
Claudia Vivori
YSYerma Pareja Sanchez
Yerma Pareja Sanchez
FIFrancesca Invernizzi
Francesca Invernizzi
ACAngela Cattaneo
Angela Cattaneo
GTGiovanni Tonon
Giovanni Tonon

17 September 2019 in Cells
Verified
Journal Article
Open access
PDF file
MGMarco Gaviraghi
Marco Gaviraghi
CVClaudia Vivori
Claudia Vivori
GTGiovanni Tonon
Giovanni Tonon
The generation of new ribosomes is a coordinated process essential to sustain cell growth. As such, it is tightly regulated according to cell needs. As cancer cells require intense protein translation to ensure their enhanced growth rate, they exploit various mechanisms to boost ribosome biogenesis. In this review, we will summarize how oncogenes and tumor suppressors modulate the biosynthesis of the RNA component of ribosomes, starting from the description of well-characterized pathways that converge on ribosomal RNA transcription while including novel insights that reveal unexpected regulatory networks hacked by cancer cells to unleash ribosome production.

31 May 2019 in Leukemia
Verified
Journal Article
Closed access
PDF file
MFM. Frenquelli
M. Frenquelli
NCN. Caridi
N. Caridi
EAE. Antonini
E. Antonini
FSF. Storti
F. Storti
VVV. Viganò
V. Viganò
GTGiovanni Tonon
Giovanni Tonon

10 October 2022 in The EMBO Journal
Verified
Journal Article
Open access
IGIlaria Gritti
Ilaria Gritti
VBVeronica Basso
Veronica Basso
DRDarawan Rinchai
Darawan Rinchai
FCFederica Corigliano
Federica Corigliano
SPSilvia Pivetti
Silvia Pivetti
GTGiovanni Tonon
Giovanni Tonon
The ribonuclease DIS3 is one of the most frequently mutated genes in the hematological cancer multiple myeloma, yet the basis of its tumor suppressor function in this disease remains unclear. Herein, exploiting the TCGA dataset, we found that DIS3 plays a prominent role in the DNA damage response. DIS3 inactivation causes genomic instability by increasing mutational load, and a pervasive accumulation of DNA:RNA hybrids that induces genomic DNA double‐strand breaks (DSBs). DNA:RNA hybrid accumulation also prevents binding of the homologous recombination (HR) machinery to double‐strand breaks, hampering DSB repair. DIS3‐inactivated cells become sensitive to PARP inhibitors, suggestive of a defect in homologous recombination repair. Accordingly, multiple myeloma patient cells mutated for DIS3 harbor an increased mutational burden and a pervasive overexpression of pro‐inflammatory interferon, correlating with the accumulation of DNA:RNA hybrids. We propose DIS3 loss in myeloma to be a driving force for tumorigenesis via DNA:RNA hybrid‐dependent enhanced genome instability and increased mutational rate. At the same time, DIS3 loss represents a liability that might be therapeutically exploited in patients whose cancer cells harbor DIS3 mutations.